Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.55 |
| ▸ | ITGAV | P06756 | 20/20 | 0.55 |
| ▸ | ITGA2B | P08514 | 12/20 | 0.52 |
| ▸ | ITGB5 | P18084 | 8/20 | 0.51 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22009145 | 0.84 | ITGB3 (0.55) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL7912615 | 0.79 | ITGB3 (0.79) | ITGB3ITGAVITGA2B | |
| Hydrochloric Acid SCHEMBL7910150 | 0.78 | ITGB3 (0.77) | ITGB3ITGAVITGA2B | |
| SCHEMBL7380492 | 0.76 | ITGB3 (0.72) | ITGB3ITGAVITGA2B | |
| SCHEMBL8344741 | 0.75 | ITGB3 (0.63) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL29701375 | 0.73 | ITGB3 (0.67) | ITGB3ITGAVITGB5ITGB1 | |
| SCHEMBL760607 | 0.72 | ITGB3 (0.69) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL4806988 | 0.72 | ITGAV (0.55) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL2925786 | 0.71 | ITGB3 (0.62) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL23542448 | 0.71 | ITGB3 (0.55) | ITGB3ITGAVITGB5ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20210276975-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2021-09-09 | — | — | US | disclosed |
| US-11046669-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-11040955-B2 | Inhibitors of (alpha-v)(beta-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2021-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210276975-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | ITGB3 11/4885ITGAV 3/4885ITGA2B 10/4885 |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | ITGB3 12/4885ITGAV 3/4885ITGA2B 10/4885 |
| US-11040955-B2 | Inhibitors of (alpha-v)(beta-6) integrin | ITGB6, ITGA6, ITGAV | ITGB3 11/4885ITGAV 3/4885ITGA2B 10/4885 |
| US-11046669-B2 | Inhibitors of (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | ITGB3 12/4885ITGAV 3/4885ITGA2B 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.